These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 12183901

  • 1. [Therapeutic monitoring of cyclosporine A].
    Komzáková I, Safarcík K, Brozmanová H, Grundmann M.
    Ceska Slov Farm; 2002 Jul; 51(4):159-67. PubMed ID: 12183901
    [Abstract] [Full Text] [Related]

  • 2. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F.
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [Abstract] [Full Text] [Related]

  • 3. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H, Okuyama K, Konno O, Jojima Y, Akashi I, Nakamura Y, Iwamoto H, Hama K, Iwahori T, Uchiyama M, Ashizawa T, Matsuno N, Nagao T, Hirano T, Oka K.
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [Abstract] [Full Text] [Related]

  • 4. [A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
    Halacová M, Jedlicková B, Průsa R.
    Ceska Slov Farm; 2003 Nov; 52(6):267-71. PubMed ID: 14661365
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic drug monitoring of cyclosporine: 20 years of progress.
    Kahan BD.
    Transplant Proc; 2004 Mar; 36(2 Suppl):378S-391S. PubMed ID: 15041372
    [Abstract] [Full Text] [Related]

  • 6. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F, Scolletta S, Berti L, Maccherini M, Federici D, Bernazzali S, Lisi G, Chiavarelli M.
    Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
    [Abstract] [Full Text] [Related]

  • 7. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
    Sugioka N, Kokuhu T, Okamoto M, Yoshimura N, Ito Y, Shibata N, Takada K.
    J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K.
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [Abstract] [Full Text] [Related]

  • 9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 10. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M, Citterio F, Ghio L, Romagnoli J, Edefonti A, Berardinelli L, Castagneto M.
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
    Sommerer C, Konstandin M, Dengler T, Schmidt J, Meuer S, Zeier M, Giese T.
    Transplantation; 2006 Nov 27; 82(10):1280-5. PubMed ID: 17130775
    [Abstract] [Full Text] [Related]

  • 13. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
    Glanville AR, Morton JM, Aboyoun CL, Plit ML, Malouf MA.
    J Heart Lung Transplant; 2004 Oct 27; 23(10):1170-4. PubMed ID: 15477111
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O, Akashi I, Hama K, Iwahori T, Ashizawa T, Hirano T, Oka K, Matsuno N, Nagao T.
    Transplant Proc; 2005 May 27; 37(4):1725-7. PubMed ID: 15919445
    [Abstract] [Full Text] [Related]

  • 15. [Problems associated with the use and monitoring of cyclosporin. Experience at a Clinical Pharmacology Service].
    Loffreda A, Contaldi C, Santis DD, Marabese I, Chiaiese C, Formato P, Motola G, Russo F, D'Alessio O, Lampa E, Rossi F.
    Minerva Med; 1997 Dec 27; 88(12):543-9. PubMed ID: 9540786
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacologic monitoring and outcomes of cyclosporine.
    Pollard SG.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):404S-407S. PubMed ID: 15041375
    [Abstract] [Full Text] [Related]

  • 18. Flow cytometry-based pharmacodynamic monitoring after organ transplantation.
    Dieterlen MT, Eberhardt K, Tarnok A, Bittner HB, Barten MJ.
    Methods Cell Biol; 2011 Mar 27; 103():267-84. PubMed ID: 21722807
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic monitoring of cyclosporine.
    Woo J.
    Ann Clin Lab Sci; 1994 Mar 27; 24(1):60-8. PubMed ID: 8147569
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D, Kiberd B, Belitsky P, Fraser A, Balbontin F, Lawen J.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.